|

Sacituzumab Tirumotecan (sac-TMT) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: MK-2870, SKB264

Pipeline

Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1

Indications

  • Gastroesophageal Junction1
  • Gastroesophageal Adenocarcinoma1
  • Esophageal Neoplasms1
  • Esophageal Cancer1
  • Cancer1

Tucson, Arizona1 trial

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.